<DOC>
	<DOCNO>NCT02679131</DOCNO>
	<brief_summary>A phase I , open-label , nonrandomized study determine PK profile belinostat patient relapsed/refractory solid tumor hematological malignancy patient renal impairment . Eligible patient assign 1 4 cohort ( A , B , C D ) base level renal function ( normal , mild , moderate , severe renal impairment ) receive belinostat dose A normal mild renal impairment , dose B moderate severe renal impairment .</brief_summary>
	<brief_title>To Evaluate Safety Pharmacokinetics Belinostat Patients Who Have Mild , Moderate Severe Renal Impairment .</brief_title>
	<detailed_description>Study Design : A phase I , open-label , nonrandomized study determine safety pharmacokinetics belinostat patient relapsed/refractory solid tumor hematological malignancy determine PK profile patient renal impairment . Eligible patient assign 1 4 cohort ( A , B , C D ) base level renal function ( normal , mild , moderate , severe renal impairment ) receive belinostat dose A normal mild renal impairment , dose B moderate severe renal impairment . Enrollment cohort occur simultaneously rather sequentially except follow instance : Before patient enrol Cohort D , safety assess least 1 patient Cohort C end Cycle 6 . If patient Cohort C experience toxicity least Grade 3 severity , Cohort D proceed reduce start dose . Belinostat administer via 30-minute intravenous ( IV ) infusion daily Days 1 5 21-day cycle ( 6 cycle ) . Clinical safety monitor patient , two dose reduction start dose ( le 250mg/m^2 ) allow base pre-defined criterion . If patient tolerate reduce dose due Grade 3 4 toxicity , belinostat administration must discontinue . Dose escalation allow . Blood sample PK analysis collect Day 1 Day 3 , urine sample PK analysis collect Day 1 Day 4 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>1 . Patient diagnose advanced solid tumor advance hematological malignancy relapsed/refractory , standard salvage therapy exist . 2 . Patient must receive least 1 prior therapy current malignancy recover toxicity prior therapy screening . 3 . Patient either normal impaired renal function . 4 . Patient adequate hematological hepatic function . 1 . Patient acute progressive renal impairment related disease cause ( eg , toxicity , obstructive uropathy due retroperitoneal disease , proteinuria , nephrotic syndrome ) , require dialysis . 2 . Patient acute HBV HCV 3 . Patient known human immunodeficiency virus ( HIV ) positive diagnosis . 4 . Patient previous exposure belinostat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>relapsed/refractory solid tumor</keyword>
	<keyword>beleodaq</keyword>
	<keyword>renal impairment</keyword>
	<keyword>belinostat</keyword>
	<keyword>hematological malignancy</keyword>
</DOC>